 | |
| Clinical data | |
|---|---|
| Trade names | Cerianna |
| Other names | [18F]16α-Fluoroestradiol; [18F]16α-Fluoroestra-1,3,5(10)-triene-3,17β-diol |
| License data | |
| Routes of administration | Intravenous injection |
| Drug class | Estrogen;Diagnostic radiopharmaceutical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Liver[1] |
| Excretion | Gallbladder andkidney[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H23[18F]O2 |
| Molar mass | 289.37 [1] |
| 3D model (JSmol) | |
| |
| |
Fluoroestradiol F-18, also known as[18F]16α-fluoroestradiol and sold under the brand nameCerianna, is aradioactive diagnostic agent indicated for use withpositron emission tomography (PET)imaging.[1][2][3][4][5] It is ananalog ofestrogen and is used to detectestrogen receptor-positivebreast cancerlesions.[1]
Chemically, fluoroestradiol F-18 is [18F]16α-fluoro-3,17β-diol-estratriene-1,3,5(10).[1]
Fluoroestradiol F-18 was approved for medical use in the United States in May 2020.[6]
